Array Biopharma (ARRY) to Release Earnings on Tuesday

Array Biopharma (NASDAQ:ARRY) will post its quarterly earnings results before the market opens on Tuesday, August 14th. Analysts expect Array Biopharma to post earnings of ($0.24) per share for the quarter.

NASDAQ:ARRY opened at $14.80 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 5.73 and a current ratio of 5.73. Array Biopharma has a one year low of $8.26 and a one year high of $20.21. The company has a market cap of $3.14 billion, a P/E ratio of -20.56 and a beta of 1.27.

In other Array Biopharma news, Director Lunsen Gil J. Van sold 21,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $15.36, for a total transaction of $330,240.00. Following the completion of the transaction, the director now owns 31,797 shares in the company, valued at approximately $488,401.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Jason Haddock sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, July 30th. The stock was sold at an average price of $14.87, for a total transaction of $371,750.00. Following the transaction, the chief financial officer now owns 80,393 shares of the company’s stock, valued at approximately $1,195,443.91. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 441,717 shares of company stock valued at $7,844,391. Company insiders own 3.18% of the company’s stock.

Several equities research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Array Biopharma from a “sell” rating to a “hold” rating in a research report on Friday. BidaskClub downgraded shares of Array Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, July 26th. Wells Fargo & Co lifted their target price on shares of Array Biopharma from $31.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, June 28th. Piper Jaffray Companies lifted their target price on shares of Array Biopharma from $21.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 27th. Finally, SunTrust Banks lifted their target price on shares of Array Biopharma to $25.00 and gave the stock a “buy” rating in a research report on Monday, June 25th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $20.90.

Array Biopharma Company Profile

Array BioPharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus.

Read More: Penny Stocks, What You Need To Know

Earnings History for Array Biopharma (NASDAQ:ARRY)

Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply